echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > ? J Exp Med: Uncovering the drivers of cellular neuroma and providing new ideas for reducing tumor volume before surgery.

    ? J Exp Med: Uncovering the drivers of cellular neuroma and providing new ideas for reducing tumor volume before surgery.

    • Last Update: 2020-08-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Percocular intercourse nervous system tumors, including neuroblastoma, ganglioneuroma, and ganglioneuroblastoma, are the most common in children's extracranial solid tumors.
    -cell neuroma originates from nerve into nerve cells, although it is a fully differentiated benign tumor, but because of its large tumor size, often invades adjacent tissue organs, the adjacent soft tissue, blood vessels, nerves and bones have an oppressive effect.
    The current treatment of cellular neuroma is limited to surgery, but complete removal is difficult, often will produce many complications including intestinal dysfunction, surgical wound healing difficulties, and so far there is no effective means of chemotherapy to reduce the size of the tumor before surgery."
    addition, the drivers of thymocytoblastoma are far from clear compared to neuroblastoma.
    , Journal of The Institute of Oncology A. Results of Professor Thomas Look's team (Dr. Tao Ting and Dr. Shi Hui are co-authors of the article): Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR retailers.
    study reveals the drivers of tyrigeal neuroma and provides new ideas for reducing tumor volume before surgery.
    The authors first analyzed the phosphorylation AKT levels of human cell neuroma and neuroblastoma samples through immunototological chemical staining, and found that 90.91 percent of cell neuroma samples expressed medium-high levels of phosphorylated AKT, while only 6.67 percent of neuroblastoma samples were able to detect the expression of phosphorylated AKT.
    , tests of AKT downstream effect proteins also showed that the positive rates of phosphorylation mTOR and S6 in cellular neuroma samples were significantly higher than those of neuroblastoma.
    the authors then successfully constructed the first zebrafish cell neuroma model using dopamine-beta-hydroxylase gene launchers to drive the expression of the continuously activated AKT (myr-AKT).
    further studies have found that zebrafish cell neuromas are highly similar to human cytoblast neuromas, both pathologically and in transcription groups.
    Using this zebrafish model for drug screening, the authors further clarified that mTOR inhibitors (including sirolimus and everolimus) can effectively reduce the volume of zebrafish cell neuroma, providing a new way of thinking for human cell neuroma to reduce tumor volume before surgery.
    overall, the study found that the AKT-mTOR-S6 signal pathway was the driver of cellular neuroma, established the first zebrafish cell neuroma model, and found that mTOR inhibitors significantly reduced the lesions of zebrafish cell neuroma.
    Since the mTOR inhibitors sirolimus and everolimus have been approved for the treatment of related pediatric diseases, the authors recommend that clinical studies be conducted on these drugs to assess their efficacy in human cellular neuroma for the benefit of the children involved.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.